Latest Astellas Pharma Stories

WASHINGTON, May 14, 2013 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Astellas Scientific and Medical Affairs, Inc. (Astellas), a U.S. affiliate of Tokyo-based Astellas Pharma Inc., has joined the health policy research organization as its newest member. Located in Northbrook, Illinois, Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable...

NORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on donation in Illinois and northwest Indiana, have collaborated to raise awareness of the need for more organ donors in the city of Chicago. As part of the...

NORTHBROOK, Ill., April 19, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Gift of Hope Organ & Tissue Donor Network, a not-for-profit organ procurement organization that coordinates organ and tissue donation and provides public education on donation in Illinois and northwest Indiana, have collaborated to raise awareness of the need for more organ donors in the state of Illinois. As part of the...

Findings are encouraging, however, as majority of respondents are generally knowledgeable about organ donation NORTHBROOK, Ill., April 15, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced results of a national survey which found that while 60 percent of respondents were familiar with their state organ donor registries and 57 percent would be willing to have their organs donated after they...

TOKYO, April 14, 2013 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be located at Astellas' Headquarters for the Americas in Northbrook, Illinois, USA and will report to Sef Kurstjens, M.D., Ph.D., newly named Chief Medical Officer at Astellas. In April 2013, Astellas established the Chief Medical Officer position in order to further integrate and enhance...

Myrbetriq is now available in pharmacies across Canada MARKHAM, ON, April 10, 2013 /CNW/ - Overactive bladder (OAB) is a chronic, debilitating condition that can have a profound, negative impact on a patient's quality of life.( 1) Many patients with OAB are plagued by depression,(2) experience a disruption in sleep,(3) limit their social activity,(4) and experience a loss of control and decreased self-esteem.(5) An estimated 2.9 million Canadian men and women(6) suffer from OAB...

TOKYO and SAN DIEGO, April 4, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503, "Astellas") today entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads. In the preclinical setting, Ambrx ADCs have demonstrated high...

CHICAGO, March 28, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bayer (OTC:BAYRY), Johnson & Johnson (NYSE:JNJ), Novo Nordisk (NYSE:NVO), AbbVie Inc. (NYSE:ABBV) and Astellas Pharma, Inc. (OTC:ALPMY). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get...

TOKYO and SAN DIEGO, March 12, 2013 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for the joint development and commercialization of FMS-like tyrosine kinase-3 (FLT3) inhibitors, including quizartinib, effective September 3, 2013. Astellas has exercised its right to terminate the worldwide license agreement signed in 2009, and over the months ahead the companies will work...

MARKHAM, ON, March 8, 2013 /CNW/ - Astellas Pharma Canada, Inc., the Canadian subsidiary of Tokyo-based Astellas Pharma Inc., announced today Health Canada's approval of Myrbetriq(TM) (mirabegron, extended-release tablets). Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency.(1 )Mirabegron, a selective b3-adrenoceptor agonist, is a "first in class" therapeutic agent with a mechanism of action...